OncoSec Medical (ONCS)
Biopharmaceutical stocks in general are bleeding-edge investments, which means they come with tons of risk and should only be handled by investors who can handle a lot of speculation and potential losses. But in the high-stakes battle to cure one of the toughest cancers, ONCS might just be able to spin risk into reward.
The company is developing a promising therapy for advanced stage metastatic melanoma, a form of skin cancer that is deadly and difficult to treat. Melanoma resists traditional cancer treatments like chemotherapy because it spreads aggressively and essentially hides in plain sight — new drugs aim to supercharge the body’s own immune system to seek and destroy these cancer cells and shrink tumors.
Last week, ONCS released positive Phase 2 clinical data on its DNA-based ImmunoPulse treatment. More than 61% of patients in the trial experienced a reduction in the size of at least one tumor, and data suggests the treatment may trigger an anti-tumor response throughout the body — not just in the specific location treated. That would be a powerful weapon in the arsenal for treating this disease.
ONCS is up 25% since the trial data was released last week and is up about 120% year to date. While OncoSec faces tough competition from Big Pharma and other biotech firms in the melanoma space, at less than 50 cents per share, it could see huge upside if the treatment takes off. But again, that comes with a huge amount of risk. You’re essentially playing the Mega Millions Jackpot with this stock.
As of this writing, Susan J. Aluise did not hold a position in any of the aforementioned securities.